American Association for Cancer Research
00085472can200104-sup-235346_4_supp_6368379_qc4zww.pdf (1.19 MB)

Supplementary Figures from The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

Download (1.19 MB)
journal contribution
posted on 2023-03-31, 03:45 authored by Annaïck Carles, Genny Trigo-Gonzalez, Qi Cao, S.-W. Grace Cheng, Michelle Moksa, Misha Bilenky, David G. Huntsman, Gregg B. Morin, Martin Hirst

File containing supplemental figures and legends


Terry Fox Research Institute Program Project



The somatic missense point mutation c.402C>G (p.C134W) in the FOXL2 transcription factor is pathognomonic for adult-type granulosa cell tumors (AGCT) and a diagnostic marker for this tumor type. However, the molecular consequences of this mutation and its contribution to the mechanisms of AGCT pathogenesis remain unclear. To explore these mechanisms, we engineered V5-FOXL2WT- and V5-FOXL2C134W–inducible isogenic cell lines and performed chromatin immunoprecipitation sequencing and transcriptome profiling. FOXL2C134W associated with the majority of the FOXL2 wild-type DNA elements as well as a large collection of unique elements genome wide. This model enabled confirmation of altered DNA-binding specificity for FOXL2C134W and identification of unique targets of FOXL2C134W including SLC35F2, whose expression increased sensitivity to YM155. Our results suggest FOXL2C134W drives AGCT by altering the binding affinity of FOXL2-containing complexes to engage an oncogenic transcriptional program. A mechanistic understanding of FOXL2C134W-induced regulatory state alterations drives discovery of a rationally designed therapeutic strategy.